12 Results Found for “semaglutide”
At ESC Congress 2026, Dr Rami Abu Fanne (Hillel Yaffe Medical Center and Hadassah Medical Center, The Hebrew University of Jerusalem) presented an analysis exploring whether baseline vitamin D levels were associated with metabolic response to semaglutide in people with type 2 diabetes. The study included 5,300 adults and found that higher baseline vitamin D levels were associated with greater improvements in glycemic control and BMI after 12 months of treatment, although no association was observed with lipid outcomes. Dr Abu Fanne spoke to touchCARDIO about the findings and the questions they raise for future research.
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
Dr Arasi Maran explores practical strategies for integrating lifestyle interventions into the management of complex coronary artery disease, including how to prioritise modifiable risk factors, communicate recommendations effectively and support sustained behaviour change. She also discusses the role of imaging, reliable health information and patient-centred approaches to improving adherence.
The American Diabetes Association has released its 2026 Standards of Care, reflecting major advances in diabetes and cardiometabolic management. In this Q&A, Dr Robert Gabbay (Joslin Diabetes Center, Boston, MA, USA) discusses expanded roles for GLP-1–based therapies, updated cardiovascular risk targets, and a growing emphasis on integrated, whole-person care with important implications for cardiovascular clinical practice.
Epicardial adipose tissue (EAT) is a fat collection directly adjacent to the myocardium and coronary vasculature, lacking any separation and sharing the same circulation.1,2 This anatomy enables direct signalling between EAT and the surrounding tissue, positioning EAT as a central ...
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular risk reduction.
June was a dynamic month in cardiovascular medicine, marked by notable regulatory approvals and clinical trial progress across several therapeutic areas. Advances in hypertension management, lipid lowering and cardiometabolic care continue to shape the treatment landscape, while evolving data in pulmonary arterial hypertension underscore the importance of ongoing innovation. This month’s roundup highlights the latest developments poised to impact clinical practice and patient outcomes.
Cardiovascular disease (CVD) is a significant cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). An estimated 60–80% of patients with T2DM die of cardiovascular events.1,2 A bidirectional relationship has been noted between heart failure (HF) ...
A new study in the BMJ has analyzed cardiovascular disease (CVD) trends among 22 million UK residents over the last 20 years, revealing both progress and persistent challenges. The research shows a significant decrease in heart attacks and strokes, thanks to better ...
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Glucagon-like peptide 1 (GLP-1) receptor agonists piqued our interest when Marso et al. demonstrated that liraglutide significantly reduced cardiovascular events (CVEs) in persons with type 2 diabetes mellitus (T2DM) who were at a high cardiovascular (CV) risk compared with placebo in ...
Atrial fibrillation (AF) is the most common cardiac arrhythmia observed in clinical practice worldwide.1 The incidence of AF is around 0.1% in individuals under 55 years old and 9% in those aged over 80.2 The global prevalence of AF is estimated to be around 44 ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.